Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
BACKGROUND: Octreotide treatment may be associated with gall stone development in up to 50% of patients with acromegaly. Two new sustained-release formulations of somatostatin analogue have been recently developed: lanreotide SR (Somatuline) and octreotide LAR (Sandostatin LAR). The incidence of gal...
Main Authors: | Turner, H, Lindsell, DR, Vadivale, A, Thillainayagam, A, Wass, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
1999
|
Similar Items
-
A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
by: Turner, H, et al.
Published: (1999) -
Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
by: Turner, H, et al.
Published: (2004) -
Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
by: Ramírez, C, et al.
Published: (2012) -
Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
by: Karavitaki, N, et al.
Published: (2008) -
A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide.
by: Kelly, P, et al.
Published: (2010)